UnitedHealth Group's Q4 and full-year earnings call revealed a mixed bag, with the company achieving record annual sales and strong growth in its Optum segment, but also facing challenges from ACA implementation and Medicare funding pressures. Despite these headwinds, management expressed confidence in its ability to offset reductions and deliver earnings growth in 2014. The company's diversified business profile, cost-saving measures, and strategic expansions suggest potential for long-term growth, but the near-term outlook is cloudy due to uncertainties surrounding Medicare Advantage funding and ACA implementation. 

[1]